---
title: "ProQR Therapeutics N.V. (PRQR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PRQR.US.md"
symbol: "PRQR.US"
name: "ProQR Therapeutics N.V."
industry: "Biotechnology"
datetime: "2026-04-16T07:46:10.162Z"
locales:
  - [en](https://longbridge.com/en/quote/PRQR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PRQR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PRQR.US.md)
---

# ProQR Therapeutics N.V. (PRQR.US)

## Company Overview

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.proqr.com](https://www.proqr.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:16.000Z

**Overall: D (0.71)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 276 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -10.44% |  |
| Net Profit YoY | -62.71% |  |
| P/B Ratio | 3.62 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 209668517.36 |  |
| Revenue | 18835267.80 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -61.17% | E |
| Profit Margin | -258.05% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -10.44% | E |
| Net Profit YoY | -62.71% | D |
| Total Assets YoY | -24.19% | E |
| Net Assets YoY | -37.04% | E |
| Cash Flow Margin | 125.14% | B |
| OCF YoY | -10.44% | E |
| Turnover | 0.12 | E |
| Gearing Ratio | 56.21% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - ProQR Therapeutics N.V.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-10.44%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-62.71%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.62",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "209668517.36",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "18835267.80",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-61.17%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-258.05%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-10.44%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-62.71%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-24.19%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-37.04%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "125.14%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-10.44%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.12",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "56.21%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.31 | 356/393 | - | - | - |
| PB | 3.62 | 264/393 | 3.31 | 2.82 | 2.33 |
| PS (TTM) | 11.13 | 165/393 | 12.65 | 10.82 | 8.84 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-15T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 88% |
| Overweight | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.99 |
| Highest Target | 14.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PRQR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PRQR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PRQR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PRQR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**